Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors | Zendy

Tuğba Gür | Zendy; Gülşen Enterili | Zendy; Necip Pirinççi | Zendy; Canan Demir | Zendy; Halit Demir | Zendy; Mehmet Kaba | Zendy; Hüseyin Aksel Eren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors

Author(s) -

Tuğba Gür,

Gülşen Enterili,

Necip Pirinççi,

Canan Demir,

Halit Demir,

Mehmet Kaba,

Hüseyin Aksel Eren

Publication year - 2017

Publication title -

medical science and discovery

Language(s) - English

Resource type - Journals

ISSN - 2148-6832

DOI - 10.17546/msd.292489

Subject(s) - arylesterase , paraoxonase , nitric oxide , medicine , pathogenesis , oxidative stress , antioxidant , cancer , reactive oxygen species , endocrinology , pon1 , pharmacology , biochemistry , chemistry , genotype , gene

Objective: Reactive oxygen species (ROS) and antioxidant capacity have been implicated in the pathogenesis of various diseases, and cancers. Oxidative stress can cause tumor angiogenesis and may be carcinogenic. However, the relationship between antioxidant capacity and various cancers has been researched in several clinical trials. Materials and Methods: In this study, we aimed to identify serum Nitric Oxide (NO), Arylesterase (ARE) and paraoxonase (PON) activities in patients with renal tumors. Serum ARE, PON and NO levels were measured by spectrophotometer. Results: Increased activity of serum nitric oxide (NO) was determined in cancer group. Serum Arylesterase (ARE) were significantly lower in the patient group than the control group. Increased activity of Serum paraoxonase (PON) were detected in the control group (p < 0.05). Conclusion: Our results indicates that Nitric oxide (NO), arylesterase (ARE) and paraoxonase (PON) activities may play an important role in the pathogenesis of renal cell cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research